Xspray Pharma AB (publ) (STO:XSPRAY)
15.60
+0.02 (0.13%)
Jul 24, 2026, 4:18 PM CET
Xspray Pharma AB Revenue
Xspray Pharma AB had revenue of 557.00K SEK in the quarter ending March 31, 2026, a decrease of -71.02%. This brings the company's revenue in the last twelve months to 5.07M, up 30.46% year-over-year. In the year 2025, Xspray Pharma AB had annual revenue of 6.43M with 206.87% growth.
Revenue (ttm)
5.07M
Revenue Growth
+30.46%
P/S Ratio
299.57
Revenue / Employee
102.75K
Employees
24
Market Cap
738.75M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.43M | 4.34M | 206.87% |
| Dec 31, 2024 | 2.10M | -29.67M | -93.40% |
| Dec 31, 2023 | 31.77M | 29.59M | 1,357.20% |
| Dec 31, 2022 | 2.18M | 1.52M | 232.32% |
| Dec 31, 2021 | 656.00K | -708.00K | -51.91% |
| Dec 31, 2020 | 1.36M | 990.00K | 264.71% |
| Dec 31, 2019 | 374.00K | 11.00K | 3.03% |
| Dec 31, 2018 | 363.00K | -793.00K | -68.60% |
| Dec 31, 2017 | 1.16M | -20.04M | -94.55% |
| Dec 31, 2016 | 21.19M | 16.57M | 358.36% |
| Dec 31, 2015 | 4.62M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cantargia AB | 317.21M |
| Genovis AB (publ.) | 142.12M |
| Oncopeptides AB | 83.24M |
| Intervacc AB | 18.89M |
| Corline Biomedical AB | 10.67M |
| Medivir AB | 9.01M |
| FluoGuide | 349.42K |
| Infant Bacterial Therapeutics AB | -1.00K |
Xspray Pharma AB News
- 3 months ago - Xspray Pharma AB Quarterly report: Q1 2026 - Filings
- 5 months ago - Xspray Pharma AB Annual report: Q4 2025 - Filings
- 5 months ago - Xspray Pharma AB Quarterly report: Q4 2025 - Filings
- 9 months ago - Xspray Pharma AB Quarterly report: Q3 2025 - Filings
- 10 months ago - Xspray Pharma AB Press release: FDA Announcement - Filings
- 1 year ago - Xspray Pharma AB Quarterly report: Q2 2025 - Filings